Similarly, denosumab also led to an increase in tumor-infiltrating lymphocytes (TILs), B and T lymphocytes, and CD4+ and CD8+ T cells within luminal and HER2+ breast tumors62. This evidence concerns the gene CD4 and neoplasm.